Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Redefining penems.
Dalhoff A, Janjic N, Echols R. Dalhoff A, et al. Among authors: echols r. Biochem Pharmacol. 2006 Mar 30;71(7):1085-95. doi: 10.1016/j.bcp.2005.12.003. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413506 Review.
Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study.
Leibovitz E, Piglansky L, Raiz S, Greenberg D, Hamed KA, Ledeine JM, Press J, Leiberman A, Echols RM, Pierce PF, Jacobs MR, Dagan R. Leibovitz E, et al. Among authors: echols rm. Pediatr Infect Dis J. 2003 Nov;22(11):943-9. doi: 10.1097/01.inf.0000095468.89866.14. Pediatr Infect Dis J. 2003. PMID: 14614364 Clinical Trial.
Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children.
Sher L, Arguedas A, Husseman M, Pichichero M, Hamed KA, Biswas D, Pierce P, Echols R. Sher L, et al. Among authors: echols r. Pediatr Infect Dis J. 2005 Apr;24(4):301-8. doi: 10.1097/01.inf.0000157084.35865.ba. Pediatr Infect Dis J. 2005. PMID: 15818288 Clinical Trial.
Gatifloxacin therapy for children: turn on the light.
Echols R, Hamed K, Arguedas A, Dagan R, Sher L, Sáez-Llorens X, Pichichero ME. Echols R, et al. Clin Infect Dis. 2005 Dec 15;41(12):1824-5. doi: 10.1086/498318. Clin Infect Dis. 2005. PMID: 16288415 No abstract available.
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: echols r. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
124 results